Research ArticleOpen Access [12]. We have also recently demonstrated an additive in vivo anti-cancer effect of nisin in conjunction with a conventional chemotherapeutic; doxorubicin (DOX) against murine skin carcinogenesis [13]. The present study further delineates the underlying mechanism of nisin-DOX additive anticancer action in vivo (in a murine model) and in vitro (using HaCaT cell lines) against skin carcinogenesis.
Materials and Methods
MaterialAll the chemicals used in the present study were of analytical grade and were obtained from standard companies. ELISA plates, tissue culture plates (96 /8 well), culture dishes, Serological plates, Roux culture bottles, 0.2µm sterile syringe filters (non-pyrogenic). DMBA (7,12-Dimethylbenzylanhracene), TPA (12-O-tetradecanoylphorbol-13-acetate), RPMI 1640 (Rose Well Park Memorial Institute Lab no. 1640) (Hi-media, India), doxorubicin nisinand3-(4,5-dimethylthiazol2yl)-2,5-diphenyl tetrazolium bromide were procured from Sigma Aldrich.N-phenyl-1-napthylamine (NPN), bovine serum albumin (BSA), 5,5-dithiobis-2-nitrobenzoic acid (DTNB), thiobarbituric acid (TBA), ethanol, formaldehyde, hydrogen peroxide (H 2 O 2 ), benzene, paraffin wax, xylene, trichloroacetic acid (TCA), sodium chloride (NaCl), EDTA, Folin's Reagent, sodium carbonate, copper sulphate,
AbstractBackground: Multidrug resistance exhibited by cancerous cells has proved to be a big hurdle in the development of an effective anti-cancer therapy. We previously demonstrated nisin-doxorubicin adjunct therapy to exhibit strong additive anti-cancer effect against DMBA -induced murine skin carcinogenesis but the mechanism remained unexplored.
Methods:The in vivo tumoricidal activity of the combination was validated in terms of animal bioassay observations while ex vivo anti-cancer effect was monitored by employing HaCat cell lines.
Results:The combination was found to be additive in vivo as evidenced by larger decreases in mean tumor burden and tumor volumes. The IC 50 values of nisin and DOX alone were evaluated to be 16 µg/ml and 4 µg/ml respectively while the sub-inhibitory concentration of DOX was reduced to 2 µg/ml when nisin was used as an adjunct. Q values calculated using MTT assays indicated the combination to be synergetic than additive. The mechanism was found to involve enhanced membrane permeabilization as well as reduced expression of NF-Κb, TNF-α, TNF-β, IL-1 and IL-6.
Conclusion:As combined effect of nisin and DOX even at halved concentrations was significantly higher than either drug alone, these observations might help in lowering the chemotherapeutic doses of DOX thereby decreasing its associated side effects.